Mekinist
Mekinist ingredients
| Active ingredient | Strength |
|---|---|
| Trametinib Dimethyl Sulfoxide | .05 mg/mL, .5 mg/1, 2 mg/1 |
What Mekinist is used for
The FDA lists the approved uses on the official label (below). In the EU, trametinib is approved as Spexotras for:
Low-grade glioma Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. High-grade glioma Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Mekinist
- Generic name
- Trametinib
- Made by
- Novartis Pharmaceuticals Corporation
- Forms
- Powder, For Solution, Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA217513
- On the US market since
- 2016
Official information
- Mekinist prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Trametinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Mekinist?
Mekinist (Trametinib) is a cancer medicine made by Novartis Pharmaceuticals Corporation, approved by the US FDA.
What are the ingredients of Mekinist?
Mekinist contains Trametinib Dimethyl Sulfoxide (.05 mg/mL, .5 mg/1, 2 mg/1).
Is Mekinist approved in Europe?
The same active substance is approved in the EU as Spexotras.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA